A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration

Shin Wakatsuki, Jun‐ichi Suzuki, Masahito Ogawa, Mayumi Masumura, Susumu Muto, Tomoko Shimizu, Kiyoshi Takayama, Akiko Itai, Mitsuaki Isobe

Expert Opinion on Therapeutic Targets · 2008 · 18 citations · 17 references

Concepts

Abstract

OBJECTIVE: Amplification of inflammatory response in the non-infarct area plays an important role in the pathogenesis of ventricular remodeling after myocardial ischemia. Activation of nuclear factor-kappa B (NF-kappaB) is involved in this amplification through a positive feedback loop of pro- inflammatory cytokines. We investigated the efficacy of IKK blockade with IMD-0560, a novel inhibitor of IKK, in a rat myocardial ischemia model. METHODS/RESULTS: Left coronary artery occlusion (28 days) was carried out in Sprague-Dawley rats. Daily intraperitoneal injections of IMD-0560 (5 mg/kg) were done after the operation. Treatment with IMD-0560 significantly improved cardiac function as indicated by the preservation of fractional shortening and lower serum brain natriuretic peptide level. Histological analysis showed that IMD-0560 treatment suppressed thinning in the infarcted area compared with vehicle-treated hearts. Moreover, in situ zymography showed matrix metalloprotease-9 activity was inhibited in the infarct area. CONCLUSION: We revealed that the IKK blockade is potent for the suppression of chronic ventricular remodeling after myocardial ischemia.

References

17